Citizens reiterates Omada Health stock rating ahead of Q3 results
Citizens maintained a Market Outperform rating and $32 price target for Omada Health (NASDAQ:OMDA), citing its diversified solutions and growth prospects. The stock has risen 31% in six months, with 48% revenue growth in the past year. Q2 2026 revenue was $88M, up 43% YoY, with adjusted EPS of $0.08. The company raised its full-year revenue and EBITDA outlook, achieving GAAP profitability.
How this was made
The 30-second read
Why it matters
The reaffirmed rating and target may keep the stock in focus but adds little new information.
Market read
Limited; mainly a repeat of existing analyst coverage.
What to watch
Potential competitive pressure from larger health‑tech players could limit upside.
Background
The article is an analyst note reiterating a rating and price target for Omada Health after its recent earnings beat and revenue growth.
Ticker impact
Citizens reiterated a Market Outperform rating and $32 price target for Omada Health, citing its Q2 results and revenue growth.
likely upward pressure as the market prices in the higher $32 target versus current $19.24 price
Rating and target are unchanged but reaffirmed; investors may view the target as a catalyst for buying.
Market effects
None beyond reaffirming health‑tech sector outlook.
U.S. market only.
Limited.
Counterpoint
The rating may be overly optimistic given the modest size of the company.
Key entities
- AnalystCitizens
Research firm providing the rating and price target.
- CompanyOmada Health Inc
Health‑tech firm whose stock is the subject.
